| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
BASIC SCIENCE |





*Department of Nephrology,
Monash University Department of Medicine, and
Department of Pathology, Monash Medical Centre, Clayton, Victoria, Australia; and
Department of Anatomical Pathology, St. Vincents Hospital, Fitzroy, Victoria, Australia.
Correspondence to Dr. David J. Nikolic-Paterson, Department of Nephrology, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria 3168, Australia. Phone: 61-3-9594 3535; Fax: 61-3-9594-6530; E-mail: david.nikolic-paterson{at}med.monash.edu.au
| Abstract |
|---|
|
|
|---|
-smooth muscle actinpositive myofibroblasts, but few macrophages or T cells showed ERK activation. There was a significant correlation between glomerular p-ERK+ and PCNA+ cells and between tubular p-ERK+ and PCNA+ cells. Glomerular p-ERK+ cells correlated with glomerular cellularity and the percentage of glomeruli with segmental lesions. Tubular p-ERK+ cells correlated with renal dysfunction and interstitial fibrosis and tubular atrophy. In conclusion, activation of the ERK pathway in human glomerulopathies correlates with cell proliferation, histologic lesions, and renal dysfunction. ERK activation may promote renal repair through tubular proliferation while promoting renal fibrosis via proliferation of glomerular and interstitial myofibroblasts. | Introduction |
|---|
|
|
|---|
Many studies have examined the factors that drive pathologic cell proliferation in human and experimental renal disease. A number of growth factors have been identified that induce proliferation of glomerular mesangial cells and myofibroblasts in cell culture and animal disease models (6). However, the intracellular mechanisms by which these growth factors induce cells to enter the cell cycle remain poorly understood.
Activation of the extracellular-signal regulated kinase (ERK) pathway plays an important role in the response of many cell types to extracellular stimuli, such as growth factors, cytokines, osmotic stress, stretch, reactive oxygen species, and high glucose levels (7). After binding of ligands, such as platelet-derived growth factor and angiotensin II, to their respective receptors on the cell surface, a cascade of phosphorylation events leads to dual phosphorylation of the Thr-Glu-Try motif in the two isoforms of ERK (ERK1 and ERK2). The dual-phosphorylated form of ERK (p-ERK) is then an active kinase and is able to phosphorylate a number of transcription factor targets and thus alter the pattern of gene transcription. The best characterized feature of this pathway is that it provides the link between the binding of a growth factor to its cell-surface receptor and movement of the cell from G0 to the G1 phase of the cell cycle (8). In vitro studies have identified an important role for the ERK pathway in the proliferation of cultured mesangial cells, tubular epithelial cells, and fibroblasts (913). Recently, we identified an association between ERK activation and proliferation of tubular epithelial cells and interstitial myofibroblasts in a time-course study of the obstructed rat kidney (14). Also, ERK activation has been identified in proliferating cystic tubules in rats with autosomal-dominant polycystic kidney disease (15). Furthermore, glomerular ERK activation occurs in the rat Thy-1 model of mesangioproliferative nephritis and blockade of the ERK pathway results in a significant reduction in mesangial cell proliferation in this disease model (16,17). However, nothing is known of ERK activation in normal adult human kidney or human renal disease.
The aims of the study presented here were to identify the cell types in which the ERK pathway is activated in a variety of human glomerulopathies and to determine whether ERK activation is associated with cell proliferation, histologic damage, and renal dysfunction.
| Materials and Methods |
|---|
|
|
|---|
|
-smooth muscle actin (
-SMA; Sigma-Aldrich, Castle Hill, New South Wales, Australia); KP1, anti-CD68, label monocytes, and macrophages (Serotec, Oxford, UK); rabbit antiaquaporin 2 (AQP-2; Calbiochem, San Diego, CA) was used as a marker of collecting ducts (CD); and UCHL1 was used recognizing human T cells (Serotec). Secondary polyclonal antibodies used were biotinylated goat anti-rabbit IgG and avidin-biotin complexes (ABC) (Vector Laboratories, Burlingame, CA); horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG and rabbit anti-goat IgG (Dako); HRP-conjugated goat anti-rabbit IgG (Silenus Laboratories, Melbourne, Australia); and complexes of HRP-conjugated mouse, goat, or rabbit anti-HRP IgG complexes (PAP) (Dako).
Western Blotting
Normal human kidney tissue (the uninvolved pole form carcinoma nephrectomies) was homogenized on ice in 2 ml of lysis buffer (10 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 2 mM Na2VO4, 1% Triton X-100, 10% glycerol, 0.5% deoxycholate, 1 mM PMSF, and 10% protease inhibitor cocktail [Sigma-Aldrich]), left on ice for 10 min with regular vortexing, and tissue debris removed by centrifugation at 15,000 x g for 20 min and the supernatant aliquotted and stored at 80°C. As a positive control for ERK activation, rat NRK49F fibroblasts were cultured in 6-ml wells, starved overnight in 0.25% FCS, and then were either left untreated (Nil) or stimulated for 10 min with 10 ng/ml human IL-1
(PeproTech, London, UK) before being lysed with the lysis buffer as described above.
Lysates (10 µg per lane) were run on 12.5% SDS-PAGE and then transferred onto nitrocellulose membranes (Amersham, Buckinghamshire, UK) by electroblotting in 25 mM Tris-HCl, pH 8.5, 192 mM glycine, 20% methanol overnight with a Bio-Rad Transblot apparatus (Bio-Rad Laboratories, Hercules, CA). Blots were blocked for 2 h in 5% nonfat milk powder in 20 mM Tris-HCl, pH 7.6, 137 mM NaCl, 1% BSA, and 0.05% Tween 20, and washed five times in 20 mM Tris-HCl, pH 7.6, 137 mM NaCl, and 0.05% Tween 20. Blots were then incubated overnight at 4°C with rabbit antip-ERK antibody in the blocking solution, washed, and then incubated for 1 h with HRP-conjugated sheep anti-rabbit IgG in binding buffer. After washing, bound antibody was detected with SuperSignal chemiluminescent substrate (Pierce, Rockford, IL). Chemiluminescent emissions were captured on Kodak XAR film. Blots were stripped and reprobed with the rabbit anti-ERK2 antibody (K-23).
Immunohistochemistry
Detection of p-ERK in 4-µm sections of formalin-fixed, paraffin-embedded tissue used the ABC method. Sections were dewaxed, microwaved for 10 min in 0.1 M sodium citrate buffer pH 6.0, washed in PBS, and then blocked in 10% normal sheep serum, 10% FCS, and 5% BSA in PBS for 30 min. A 1/100 dilution of rabbit antip-ERK1/2 antibody in 10% normal human serum and 1% BSA in PBS was added to sections overnight at 4°C. Sections then were washed three times in PBS, endogenous peroxidase inactivated in 0.6% H2O2 in methanol for 20 min, washed in PBS, and a biotin block applied (Vector Laboratories). After washing in PBS, sections were incubated with biotinylated goat anti-rabbit IgG for 45 min, washed, and incubated with the ABC complex for 45 min at room temperature. After washing in PBS, sections were developed with the diaminobenzidine substrate (Sigma-Aldrich) to produce a brown color. The specificity of p-ERK staining was confirmed by a lack of staining with no primary antibody or an isotype-matched irrelevant antibody. In addition, the antip-ERK antibody was incubated with the immunizing phospho-ERK peptide that abolished the staining reaction.
Detection of PCNA, macrophages,
-SMA, T cells, and AQP-2 used a three-layer PAP method. Sections underwent microwave heating (except for
-SMA staining), washed in PBS, and blocked for 30 min as above. Primary antibodies were applied to sections overnight at 4°C. Sections then were washed in PBS, and then incubated sequentially with HRP-conjugated secondary antibodies followed by PAP complexes. HRP was developed with Vector SG (Vector Laboratories) to give a blue-gray color.
For two-color immunostaining, sections were stained with p-ERK or
-SMA antibodies, treated with microwave oven heating to prevent antibody cross-reactivity (18), and then stained with p-ERK, KP1, or T cell antibodies with a different color development.
Samples from all cases were immunostained for p-ERK and PCNA. However, because of limitations in tissue availability, double staining for the other antibody combinations was performed on approximately three cases per disease group.
Quantification of Immunostaining
The number of cells stained positive for p-ERK or PCNA were counted in glomerular cross sections under high power (x400). All tissues contained at least 6 glomeruli, with most containing 10 to 15 glomeruli. Glomerular counts included both the capillary tuft and crescents. The number of tubular cells stained positive for p-ERK or PCNA were counted in 50 to 100 consecutive high-power (x400) cortical fields (avoiding glomeruli and large vessels) with a graticule and was expressed as the number of positive tubular cells per square millimeter.
Histopathology
Periodic acidSchiffstained sections were scored for the number of nuclei per glomerular cross section (tuft and crescent), the number of glomeruli with segmental proliferative and/or necrotic lesions, and the number of glomeruli with crescent formation (Table 2). The area of the tubulointerstitium with interstitial fibrosis and tubular atrophy was assessed by a semiquantitative score: 0 (<5%), 1 (6% to 20%), 2 (20% to 40%), and 3 (>40%). All analysis was performed on blinded slides.
|
| Results |
|---|
|
|
|---|
|
|
|
-SMA+ cells within both the tuft and the crescent (Figure 3b). However, very few glomerular macrophages or T cells showed ERK activation.
Tubular p-ERK immunostaining in FGS, lupus, and vasculitis was restricted to CD in areas of intact tubulointerstitium. However, p-ERK staining was evident in damaged tubules (Figure 2, b and d), especially those containing casts. In addition, interstitial p-ERK stained cells were seenagain, predominantly in areas of tubulointerstitial damage (Figure 2, b and d). Double immunohistochemistry identified nuclear p-ERK staining in most interstitial
-SMA+ myofibroblasts (Figure 3, c and d), whereas only rare interstitial macrophages or T cells were positive for p-ERK (data not shown). The specificity of p-ERK antibody was verified by absorption with the antibody with the immunizing ERK phosphopeptide (Figure 2f) and by Western blotting (Figure 1). The highly variable nature of the glomerular and tubular p-ERK staining across the different biopsy samples is reflected in the large SD seen in each disease group in Figure 4.
|
Proliferation of tubular epithelial cells was also highly variable across the cohort. Indeed, significant tubular cell proliferation was seen in the two "normal" cases and in some cases of TMD. This was usually present in areas of focal interstitial damage. Substantial numbers of proliferating tubular cells were also seen in the more aggressive diseases, in which proliferation of interstitial cells was also observed (Figure 2e).
Staining of serial sections identified colocalization of p-ERK+ cells and PCNA+ cells in areas of tissue damage (Figure 2, b and c). A case of vasculitis is shown in Figure 2, d and e, in which a crescentic glomerulus and an area of tubulointerstitial damage contain numerous p-ERK+ and PCNA+ cells. Whether ERK activation and PCNA expression were present within the same individual cell was not examined because ERK activation is a generally an early event that induces resting cells to move from Go into G1 phase of the cell cycle (8), whereas PCNA is not usually expressed until cells have already entered G1 phase. However, it should be pointed out that not all glomerular or tubulointerstitial areas with prominent p-ERK staining had substantial numbers of PCNA+ cells.
Correlation of ERK Activation with Cell Proliferation and Renal Dysfunction
Analyzing all disease groups as a single cohort found a significant correlation between the number of glomerular p-ERK+ and PCNA+ cells, and a significant correlation between the number of tubular p-ERK+ and PCNA+ cells (Figure 5). The number of glomerular p-ERK+ cells correlated with glomerular cellularity and the percentage of glomeruli with segmental lesions, but was of borderline significance in relation to renal function and did not correlate with proteinuria (Table 3). In contrast, the number of p-ERK+ tubular cells gave a significant correlation with renal function and interstitial damage (fibrosis and tubular atrophy), but not with proteinuria (Table 3).
|
|
| Discussion |
|---|
|
|
|---|
A clear association between ERK activation and cell proliferation was seen in the different glomerulopathies examined. This was evident by the significant correlation between the number of p-ERK+ and PCNA+ cells in glomeruli and in tubules, and by colocalization of p-ERK+ and PCNA+ cells within focal glomerular and tubulointerstitial lesions. A feature of the study was the variability of the number of p-ERK+ cells within individual biopsy samples and between individual patients with same diagnosis. This is, perhaps, not surprising, given that cell proliferation in the pathologic state is a dynamic event that occurs in bursts within focal areas. It is of note that although PCNA has been verified as a good indicator of cell proliferation, this marker has some limitations, such as a small proportion of cells expressing PCNA may not complete cell division, and that PCNA expression may be detectable in some cells for a short period after division has been completed.
Studies of cultured mesangial cells and in the rat Thy-1 model of mesangioproliferative nephritis have provided evidence of a causal link between ERK activation and mesangial cell proliferation (9,10,16,17). In the study presented here, double staining identified ERK activation in
-SMA+ cells within the glomerular capillary tuft in FGS, lupus, and vasculitis. This probably represents activation of the ERK pathway in "activated" mesangial cells, providing evidence that ERK signaling may play an important role in mesangial cell proliferation in human glomerulopathies. However, it needs to be appreciated that in some glomeruli, the
-SMA+ cells within the glomerular tuft could be myofibroblasts that have migrated from the periglomerular area through ruptures in Bowmans capsule.
We observed p-ERK staining in
-SMA+ myofibroblasts in both glomerular crescents and the interstitium in human glomerulopathies, suggesting that ERK signaling plays a role in myofibroblast proliferation, an important step in myofibroblast accumulation and development of renal fibrosis. This is consistent with studies in which PDGF-BB induced proliferation of hepatic myofibroblasts operates in an ERK-dependent fashion (13), and the finding that administration of PDGF-BB to normal rats leads to the proliferation and accumulation of
-SMA+ myofibroblasts and mild fibrosis in the renal interstitium (23). However, ERK signaling may mediate other functions in renal myofibroblasts, such as the synthesis of collagen and fibronectin (24,25), and the production of metalloproteinase-1, cyclooxygenase-2, and nitric oxide (2628).
One interesting finding was the lack of ERK activation in infiltrating macrophages and T cells. In vitro studies have shown that macrophage-colony stimulating factor (M-CSF) driven macrophage proliferation operates via the ERK pathway (29), and we have previously demonstrated the presence of local macrophage proliferation in human glomerulonephritis in association with up-regulation of renal M-CSF production (30). One possible reason for this unexpected result may be the transient nature of ERK activation after M-CSF stimulation of macrophages (31).
ERK activation in tubular epithelial cells was restricted to the CD in normal human kidney and in the different glomerulopathies where the tubulointerstitial area remained intact. However, ERK activation was prominent in damaged tubules and colocalized with tubular cell proliferation. Indeed, there was a significant correlation between tubular ERK activation and tubular cell proliferation. This is consistent with a time-course study in the obstructed rat kidney in which ERK activation preceded tubular proliferation (14), and a study in autosomal-dominant polycystic kidney disease in which ERK activation is closely associated with dysregulated tubular cell proliferation in cysts (15). In addition to proliferation, ERK activation in damaged tubules may enhance cell survival by inhibition of apoptosis (32), and promoting cell adhesion (33).
ERK activation may be a double-edged sword in renal disease. On one hand, ERK-mediated proliferation of mesangial cells and myofibroblasts may promote renal fibrosis and disease progression. Conversely, ERK activation in damaged tubules may be desirable to promote renal repair. Therefore, therapies targeting the undesirable ERK-mediated proliferation in renal disease may need to focus on the events upstream of ERK activation.
In summary, this study has localized ERK activation in normal human kidney and in a variety of glomerulopathies. ERK activation in human glomerulopathies correlates with cell proliferation, histologic lesions, and renal dysfunction. However, signaling through the ERK pathway may promote renal repair through tubular proliferation on one hand, while inducing renal fibrosis via proliferation of glomerular and interstitial myofibroblasts on the other.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. H. de Borst, S. H. Diks, J. Bolbrinker, M. W. Schellings, M. B. A. van Dalen, M. P. Peppelenbosch, R. Kreutz, Y. M. Pinto, G. Navis, and H. van Goor Profiling of the renal kinome: a novel tool to identify protein kinases involved in angiotensin II-dependent hypertensive renal damage Am J Physiol Renal Physiol, July 1, 2007; 293(1): F428 - F437. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zhang, K. A. Kernan, S. J. Collins, X. Cai, J. M. Lopez-Guisa, J. L. Degen, Y. Shvil, and A. A. Eddy Plasmin(ogen) Promotes Renal Interstitial Fibrosis by Promoting Epithelial-to-Mesenchymal Transition: Role of Plasmin-Activated Signals J. Am. Soc. Nephrol., March 1, 2007; 18(3): 846 - 859. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Flores-Benitez, A. Ruiz-Cabrera, C. Flores-Maldonado, L. Shoshani, M. Cereijido, and R. G. Contreras Control of tight junctional sealing: role of epidermal growth factor Am J Physiol Renal Physiol, February 1, 2007; 292(2): F828 - F836. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Okada, T. Inoue, T. Kikuta, Y. Watanabe, Y. Kanno, S. Ban, T. Sugaya, M. Horiuchi, and H. Suzuki A Possible Anti-Inflammatory Role of Angiotensin II Type 2 Receptor in Immune-Mediated Glomerulonephritis during Type 1 Receptor Blockade Am. J. Pathol., November 1, 2006; 169(5): 1577 - 1589. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bhalla, R. Soundararajan, A. C. Pao, H. Li, and D. Pearce Disinhibitory pathways for control of sodium transport: regulation of ENaC by SGK1 and GILZ Am J Physiol Renal Physiol, October 1, 2006; 291(4): F714 - F721. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Balkovetz Claudins at the gate: determinants of renal epithelial tight junction paracellular permeability Am J Physiol Renal Physiol, March 1, 2006; 290(3): F572 - F579. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Soundararajan, T. T. Zhang, J. Wang, A. Vandewalle, and D. Pearce A Novel Role for Glucocorticoid-induced Leucine Zipper Protein in Epithelial Sodium Channel-mediated Sodium Transport J. Biol. Chem., December 2, 2005; 280(48): 39970 - 39981. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. E. Hellman, A. J. Greco, K. K. Rogers, C. Kanchagar, D. F. Balkovetz, and J. H. Lipschutz Activated extracellular signal-regulated kinases are necessary and sufficient to initiate tubulogenesis in renal tubular MDCK strain I cell cysts Am J Physiol Renal Physiol, October 1, 2005; 289(4): F777 - F785. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Lipschutz, S. Li, A. Arisco, and D. F. Balkovetz Extracellular Signal-regulated Kinases 1/2 Control Claudin-2 Expression in Madin-Darby Canine Kidney Strain I and II Cells J. Biol. Chem., February 4, 2005; 280(5): 3780 - 3788. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |